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Background
MP29-02*, a novel intranasal formulation of azelastine
hydrochloride (AZE) and fluticasone propionate (FP)
provides significantly superior symptom relief to current
first line therapy in patients with seasonal allergic rhini-
tis (SAR) and with chronic rhinitis [1,2].
Objective
To evaluate the short- and long-term safety of MP29-
02*.
Method
4022 patients (>=12 years old) were randomized into 4,
14-day double-blind, placebo-controlled SAR trials to
receive MP29-02*, AZE, FP or placebo nasal sprays (all
given as 1 spray/nostril bid). 612 patients (>=12 years old)
were randomized into a 1-year, open-label, active-con-
trolled, parallel-group chronic rhinitis trial to receive
MP29-02* (1 spray/nostril bid) or FP nasal spray (2
sprays/nostril qd). For all studies the total daily dose of
AZE and FP was 548 g and 200 µg respectively. Safety was
assessed by incidence, type, and severity of adverse events,
vital signs and nasal examination.
Results
In all SAR studies, the treatment-related adverse events
(TRAEs) observed were those usually reported with AZE
(dysgeusia) and FP (headache and epistaxis), did not
exceed placebo in many instances (Table 1 shows results
from a representative SAR study) and were ‘mild’ in the
vast majority of cases. In the long-term study there was no
evidence for an accumulation of TRAEs over time, any
occurrence of late AEs and none were considered severe.
< 3% of subjects discontinued from the study due to an
AE. A SAE was reported by 3 MP29-02 subjects and 1 FP
subject, but none were considered treatment-related. For
all studies, changes in vital signs and nasal examinations
were similar in all groups.
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Table 1
MP4002 SAR study (14 days)
MP29-02* (n=207) FP (n=207) AZE (n=208) Placebo (n=210)
TRAE n (%) 17 (8.2%) 14 (6.8%) 16 (7.7%) 8 (3.8%)
Dysgeusia 5 (2.4%) 2 (1.0%) 7 (3.4%) 1 (0.5%)
Epistaxis 2 (1.0%) 5 (2.4%) 4 (1.9%) 2 (1.0%)
Headache 1 (0.5%) 5 (2.4%) 1 (0.5%) 3 (1.4%)
Chronic rhinitis study (52 weeks)
MP29-02* (n=404) FP (n=207)
TRAE n (%) 38 (9.4%) 23 (11.1%)
Dysgeusia 10 (2.5%) 1 (0.5%)
Epistaxis 5 (1.2%) 1 (0.5%)
Headache 4 (1.0%) 9 (4.3%)
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Conclusion
MP29-02* was well tolerated following 14 day’s use in
SAR patients with a similar safety profile as standard
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